An overview of statin-induced myopathy and perspectives for the future

References

• Gluba-Brzozka A, Franczyk B, Toth PP, et al. Molecular mechanisms of statin intolerance. Arch Med Sci. 2016 Jun 1;12(3):645–658.
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Wierzbicki AS, Statins M. Disease and mitochondria. J Clin Med. 2017 Jul 25;6(8). DOI:10.3390/jcm6080075.
   PubMed Web of Science ®Google Scholar
• Banach M, Stulc T, Dent R, et al. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol. 2016 Dec 15;225:184–196.
   PubMed Web of Science ®Google Scholar
• Skilving I, Eriksson M, Rane A, et al. Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences. Eur J Clin Pharmacol. 2016 Oct;72(10):1171–1176.
   PubMed Web of Science ®Google Scholar
• Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015 Sep;80(3):363–371.
   PubMed Web of Science ®Google Scholar
• Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clin Interv Aging. 2013;8:47–59.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015 May 1;36(17):1012–1022.
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Alvarado-Cardenas M, Pinal-Fernandez I, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018 Mar;14(3):215–224.
   PubMed Web of Science ®Google Scholar
• Pedro-Botet J, Millan Nunez-Cortes J, Chillaron JJ, et al. Severity of statin-induced adverse effects on muscle and associated conditions: data from the DAMA study. Expert Opin Drug Saf. 2016 Dec;15(12):1583–1587.
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet. 2007 Nov 24;370(9601):1781–1790.
   PubMed Web of Science ®Google Scholar
• Manoj K, Jain N, Madhu SV. Myopathy in patients taking atorvastatin: a pilot study. Indian J Endocrinol Metab. 2017 Jul-Aug;21(4):504–509.
   PubMedGoogle Scholar
• Study of the Effectiveness of Additional Reductions in C, Homocysteine Collaborative G, Armitage J, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.Lancet. 2010 Nov 13;376(9753):1658–1669.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495–1504.
   PubMed Web of Science ®Google Scholar
• Basharat P, Lahouti AH, Paik JJ, et al. Statin-induced Anti-HMGCR-associated myopathy. J Am Coll Cardiol. 2016 Jul 12;68(2):234–235.
   PubMed Web of Science ®Google Scholar
• Waters MJ, Limaye V. Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-centre cohort. Clin Rheumatol. 2018 Feb;37(2):543–547.
   PubMed Web of Science ®Google Scholar
• Panza GA, Taylor BA, Dada MR, et al. Changes in muscle strength in individuals with statin-induced myopathy: A summary of 3 investigations. J Clin Lipidol. 2015 May-Jun;9(3):351–356.
   PubMed Web of Science ®Google Scholar
• Hou T, Li Y, Chen W, et al. Histopathologic and biochemical evidence for mitochondrial disease among 279 patients with severe statin myopathy. J Neuromuscul Dis. 2017;4(1):77–87.
   PubMedGoogle Scholar
• Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016 Jul;280(1):8–23.
   PubMed Web of Science ®Google Scholar
• Keating P, Young J, George P, et al. Anti-HMGCR autoantibodies in self-limiting statin-induced myopathy. Int J Rheum Dis. 2017 Dec;20(12):2179–2181.
   PubMed Web of Science ®Google Scholar
• Camerino GM, De Bellis M, Conte E, et al. Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin. Toxicol Appl Pharmacol. 2016 Sep;1(306):36–46.
   Web of Science ®Google Scholar
• Camerino GM, Musumeci O, Conte E, et al. Risk of myopathy in patients in therapy with statins: identification of biological markers in a pilot study. Front Pharmacol. 2017;8:500.
   PubMed Web of Science ®Google Scholar
• Goodman CA, Pol D, Zacharewicz E, et al. Statin-induced increases in atrophy gene expression occur independently of changes in PGC1alpha protein and mitochondrial content. PLoS One. 2015;10(5):e0128398.
   PubMed Web of Science ®Google Scholar
• Apostolopoulou M, Corsini A, Roden M. The role of mitochondria in statin-induced myopathy. Eur J Clin Invest. 2015 Jul;45(7):745–754.
   PubMed Web of Science ®Google Scholar
• Ochs-Balcom HM, Nguyen LM, Ma C, et al. Clinical features related to statin-associated muscle symptoms. Muscle Nerve. 2019 May;59(5):537–543.
   PubMed Web of Science ®Google Scholar
• Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014 Jul;168(1):6–15.
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Ursoniu S, et al. Statin therapy and plasma coenzyme Q10 concentrations–A systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015 Sep;99:329–336.
   PubMed Web of Science ®Google Scholar
• Latkovskis G, Saripo V, Sokolova E, et al. Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy. Medicina (Kaunas). 2016;52(3):171–179.
   PubMed Web of Science ®Google Scholar
• Qu H, Guo M, Chai H, et al. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018 Oct 2;7(19):e009835.
   PubMed Web of Science ®Google Scholar
• Banach M, Serban M-C, Sahebkar A, et al. Futility of supplementation with coenzyme Q10 for statin-induced myopathy: an updated (2015) meta-analysis of randomized controlled trials. Eur Heart J. 2015 Sept 01;36:1047.
   Google Scholar
• Banach M, Mikhailidis DP, Lipid, et al. In reply–coenzyme Q10 and statin-induced myopathy. Mayo Clin Proc. 2015 Mar;90(3):420–421.
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015 Jan;90(1):24–34.
   PubMed Web of Science ®Google Scholar
• Toth PP, Patti AM, Giglio RV, et al. Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 2018 Jun;18(3):157–173.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017 Sep 5;70(10):1290–1301.
   PubMed Web of Science ®Google Scholar
• Gui YJ, Liao CX, Liu Q, et al. Efficacy and safety of statins and exercise combination therapy compared to statin monotherapy in patients with dyslipidaemia: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017 Jun;24(9):907–916.
   PubMed Web of Science ®Google Scholar
• Marz W, Laufs U. Leucocyte immunoglobulin-like receptor subfamily-B5 (LILRB5) genetic variation and statin-associated muscle symptoms: another piece in a puzzling puzzle. Eur Heart J. 2017 Dec 21;38(48):3576–3578.
   PubMed Web of Science ®Google Scholar
• Mitchell D, Guertin JR, Iliza AC, et al. Economic evaluation of a pharmacogenomics test for statin-induced myopathy in cardiovascular high-risk patients initiating a statin. Mol Diagn Ther. 2017 Feb;21(1):95–105.
   PubMed Web of Science ®Google Scholar
• Abdulrazaq M, Hamdan F, Al-Tameemi W. Electrophysiologic and clinico-pathologic characteristics of statin-induced muscle injury. Iran J Basic Med Sci. 2015 Aug;18(8):737–744.
   PubMed Web of Science ®Google Scholar
• Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013 Jan 1;127(1):96–103.
   PubMed Web of Science ®Google Scholar
• Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010 Jun;210(2):337–343.
   PubMed Web of Science ®Google Scholar
• Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006 Aug;34(2):153–162.
   PubMed Web of Science ®Google Scholar
• Isackson PJ, Wang J, Zia M, et al. RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms. Pharmacogenomics. 2018 Nov;19(16):1235–1249.
   PubMed Web of Science ®Google Scholar
• Ramakumari N, Indumathi B, Katkam SK, et al. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J. 2018 Dec;70(Suppl 3):S120–S125.
   PubMedGoogle Scholar
• Lee HH, Ho RH. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol. 2017 Jun;83(6):1176–1184.
   PubMed Web of Science ®Google Scholar
• Eng H, Scialis RJ, Rotter CJ, et al. The antimicrobial agent fusidic acid inhibits organic anion transporting polypeptide-mediated hepatic clearance and may potentiate statin-induced myopathy. Drug Metab Dispos. 2016 May;44(5):692–699.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Chen SQ, Ma LY, et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J. 2018 Dec;18(6):721–729.
   PubMed Web of Science ®Google Scholar
• Talameh JA, Kitzmiller JP. Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic genetic variants. J Pharmacogenomics Pharmacoproteomics. 2014 Apr 23;5:2.
   Google Scholar
• Liu JE, Liu XY, Chen S, et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol. 2017 Nov;73(11):1409–1416.
   PubMed Web of Science ®Google Scholar
• Hubacek JA, Dlouha D, Adamkova V, et al. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit. 2015 May 20;21:1454–1459.
   PubMed Web of Science ®Google Scholar
• Saber-Ayad M, Manzoor S, El-Serafi A, et al. Statin-induced myopathy SLCO1B1 521T>C is associated with prediabetes, high body mass index and normal lipid profile in Emirati population. Diabetes Res Clin Pract. 2018 May;139:272–277.
   PubMed Web of Science ®Google Scholar
• Hu M, Mak VW, Tomlinson B. Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet Genomics. 2012 Nov;22(11):803–806.
   PubMed Web of Science ®Google Scholar
• Carr DF, Francis B, Jorgensen AL, et al. Genomewide association study of statin-induced myopathy in patients recruited using the UK clinical practice research datalink. Clin Pharmacol Ther. 2019 Jun 20;106(6):1353–1361.
   PubMed Web of Science ®Google Scholar
• Neroldova M, Stranecky V, Hodanova K, et al. Rare variants in known and novel candidate genes predisposing to statin-associated myopathy. Pharmacogenomics. 2016 Aug;17(13):1405–1414.
   PubMed Web of Science ®Google Scholar
• Luzum JA, Kitzmiller JP, Isackson PJ, et al. GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. Cell Metab. 2015 Apr 7;21(4):622–627.
   PubMed Web of Science ®Google Scholar
• Brunham LR, Lansberg PJ, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012 Jun;12(3):233–237.
   PubMed Web of Science ®Google Scholar
• Dein E, Manno R, Syed A, et al. Ranolazine-induced elevation of creatinine kinase in the absence of statin usage. Cureus. 2018 Jun 18;10(6):e2832.
   PubMed Web of Science ®Google Scholar
• Hill FJ, McCloskey SJ, Sheerin N. From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions. BMJ Case Rep. 2015 Jun 23;2015:bcr2015209961-bcr2015209961.
   PubMedGoogle Scholar
• Siriangkhawut M, Tansakul P, Uchaipichat V. Prevalence of potential drug interactions in Thai patients receiving simvastatin: the causality assessment of musculoskeletal adverse events induced by statin interaction. Saudi Pharm J. 2017 Sep;25(6):823–829.
   PubMed Web of Science ®Google Scholar
• Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor leads to statin-induced rhabdomyolysis: a case report. Am J Case Rep. 2017 Nov;23(18):1238–1241.
   Web of Science ®Google Scholar
• Budzisz E, Nowicki M. Opinions of nephrologists on the efficacy and tolerance of statins in hemodialysis patients. Ren Fail. 2017 Nov;39(1):277–282.
   PubMed Web of Science ®Google Scholar
• Ambapkar SN, Shetty N, Dwivedy A, et al. Statin-induced rhabdomyolysis in patient with renal failure and underlying undiagnosed hypothyroidism. Indian J Crit Care Med. 2016 May;20(5):305–307.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel. Arch Med Sci. 2015 Mar 16;11(1):1–23.
   PubMed Web of Science ®Google Scholar
• Kunwar S, Parekh JD, Chilukuri RS, et al. Necrotizing autoimmune myopathy: a case report on statin induced rhabdomyolysis requiring immunosuppressive therapy. Drug Discov Ther. 2018;12(5):315–317.
   PubMed Web of Science ®Google Scholar
• Troyanov Y, Landon-Cardinal O, Fritzler MJ, et al. Atorvastatin-induced necrotizing autoimmune myositis: an emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype. Medicine (Baltimore). 2017 Jan;96(3):e5694.
   PubMed Web of Science ®Google Scholar
• Obreja E, Sequeira P, Girnita D. When should a patient with statin-induced myopathy be re-challenged? A case of necrotizing autoimmune myopathy. Case Rep Rheumatol. 2018;2018:1215653.
   PubMedGoogle Scholar
• Dixit A, Abrudescu A. A case of atorvastatin-associated necrotizing autoimmune myopathy, mimicking idiopathic polymyositis. Case Rep Rheumatol. 2018;2018:5931046.
   PubMedGoogle Scholar
• Nichols L, Pfeifer K, Mammen AL, et al. An unusual case of statin-induced myopathy: anti-HMGCoA necrotizing autoimmune myopathy. J Gen Intern Med. 2015 Dec;30(12):1879–1883.
   PubMed Web of Science ®Google Scholar
• Hilton-Jones D. Statin-related myopathies. Pract Neurol. 2018 Apr;18(2):97–105.
   PubMedGoogle Scholar
• Young JB, Ghobrial II. Autoimmune statin-induced myopathy: a case report. J Community Hosp Intern Med Perspect. 2015;5(4):28374.
   PubMed Web of Science ®Google Scholar
• Babu S, Li Y. Statin induced necrotizing autoimmune myopathy. J Neurol Sci. 2015 Apr 15;351(1–2):13–17.
   PubMed Web of Science ®Google Scholar
• Hedenmalm K, Granberg AG, Dahl ML. Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives. Eur J Clin Pharmacol. 2015 Jan;71(1):117–124.
   PubMed Web of Science ®Google Scholar
• The European Medicines Agency web site. Annex I: summary of product characteristics; 2012. [cited 2020 Feb 16]. Available from: https://www.ema.europa.eu/en/documents/product-information/vfend-epar-product-information_en.pdf
   Google Scholar
• Kellick KA, Bottorff M, Toth PP, et al. A clinician’s guide to statin drug-drug interactions. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S30–46.
   PubMed Web of Science ®Google Scholar
• Schirris TJ, Renkema GH, Ritschel T, et al. Statin-induced myopathy is associated with mitochondrial complex III inhibition. Cell Metab. 2015 Sep 1;22(3):399–407.
   PubMed Web of Science ®Google Scholar
• Bonifacio A, Sanvee GM, Bouitbir J, et al. The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity. Biochim Biophys Acta. 2015 Aug;1853(8):1841–1849.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Kimura J. Mechanism of statin-induced rhabdomyolysis. J Pharmacol Sci. 2013;123(4):289–294.
   PubMed Web of Science ®Google Scholar
• Elam MB, Majumdar G, Mozhui K, et al. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One. 2017;12(8):e0181308.
   PubMed Web of Science ®Google Scholar
• Group SC, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789–799.
   PubMed Web of Science ®Google Scholar
• Alis R, Sanchis-Gomar F, Risso-Ballester J, et al. Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomiolysis. Atherosclerosis. 2015 Mar;239(1):38–42.
   PubMed Web of Science ®Google Scholar
• Liu A, Wu Q, Guo J, et al. Statins: adverse reactions, oxidative stress and metabolic interactions. Pharmacol Ther. 2019 Mar;195:54–84.
   PubMed Web of Science ®Google Scholar
• Ahmadi Y, Ghorbanihaghjo A, Naghi-Zadeh M, et al. Oxidative stress as a possible mechanism of statin-induced myopathy. Inflammopharmacology. 2018 Jun;26(3):667–674.
   PubMed Web of Science ®Google Scholar
• Osaki Y, Nakagawa Y, Miyahara S, et al. Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy. Biochem Biophys Res Commun. 2015 Oct 23;466(3):536–540.
   PubMed Web of Science ®Google Scholar
• Kim WH, Lee CH, Han JH, et al. C/EBP homologous protein deficiency inhibits statin-induced myotoxicity. Biochem Biophys Res Commun. 2019 Jan 15;508(3):857–863.
   PubMed Web of Science ®Google Scholar
• Mikashinovich ZI, Belousova ES, Sarkisyan OG. Impairment of energy-dependent processes in the muscle tissue as a pathogenetic mechanism of statin-induced myopathy. Bull Exp Biol Med. 2017 Feb;162(4):433–435.
   PubMed Web of Science ®Google Scholar
• Zhang X, Hong S, Yen R, et al. A system to monitor statin-induced myopathy in individual engineered skeletal muscle myobundles. Lab Chip. 2018 Sep 11;18(18):2787–2796.
   PubMed Web of Science ®Google Scholar
• Banach M, Mikhailidis DP. Statin Intolerance: some practical hints. Cardiol Clin. 2018 May;36(2):225–231.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Banach M. Response letter: management of statin-induced myopathies: much demands and still (almost) empty hands! J Cachexia Sarcopenia Muscle. 2017 Jun;8(3):514–515.
   PubMed Web of Science ®Google Scholar
• Fogacci F, Banach M, Mikhailidis DP, et al. Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019 May;143:1–16.
   PubMed Web of Science ®Google Scholar
• Banach M, Patti AM, Giglio RV, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018 Jul 3;72(1):96–118.
   PubMed Web of Science ®Google Scholar
• Banach M, Bruckert E, Descamps OS, et al. The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. Atherosclerosis Suppl. 2019 Aug 17;39:e1-e8.
   PubMed Web of Science ®Google Scholar
• Wat E, Ng CF, Koon CM, et al. The protective effect of Herba Cistanches on statin-induced myotoxicity in vitro. J Ethnopharmacol. 2016 Aug 22;190:68–73.
   PubMed Web of Science ®Google Scholar
• Song M, Chen FF, Li YH, et al. Trimetazidine restores the positive adaptation to exercise training by mitigating statin-induced skeletal muscle injury. J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):106–118.
   PubMed Web of Science ®Google Scholar
• Chung HR, Vakil M, Munroe M, et al. The impact of exercise on statin-associated skeletal muscle myopathy. PLoS One. 2016;11(12):e0168065.
   PubMed Web of Science ®Google Scholar
• Kwak HB. Statin-induced myopathy in skeletal muscle: the role of exercise. J Lifestyle Med. 2014 Sep;4(2):71–79.
   PubMedGoogle Scholar
• Berent T, Berent R, Steiner S, et al. Statin-induced muscular side effects at rest and exercise - An anatomical mapping. Atherosclerosis Suppl. 2019 Aug 17;40:73–78.
   Web of Science ®Google Scholar
• Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015 Jan 15;178:111–116.
   PubMed Web of Science ®Google Scholar
• Riche KD, Arnall J, Rieser K, et al. Impact of vitamin D status on statin-induced myopathy. J Clin Transl Endocrinol. 2016 Dec;6:56–59.
   PubMedGoogle Scholar
• Khayznikov M, Hemachrandra K, Pandit R, et al. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by Vitamin D supplementation. N Am J Med Sci. 2015 Mar;7(3):86–93.
   PubMed Web of Science ®Google Scholar
• Taylor BA, Lorson L, White CM, et al. Low vitamin D does not predict statin associated muscle symptoms but is associated with transient increases in muscle damage and pain. Atherosclerosis. 2017 Jan;256:100–104.
   PubMed Web of Science ®Google Scholar
• Ovesjo ML, Skilving I, Bergman P, et al. Low Vitamin D levels and genetic polymorphism in the Vitamin D receptor are associated with increased risk of statin-induced myopathy. Basic Clin Pharmacol Toxicol. 2016 Mar;118(3):214–218.
   PubMed Web of Science ®Google Scholar
• Brahmachari B, Chatterjee S. Myopathy induced by statin-ezetimibe combination: evaluation of potential risk factors. Indian J Pharmacol. 2015 Sep-Oct;47(5):563–564.
   PubMed Web of Science ®Google Scholar
• Pennisi M, Di Bartolo G, Malaguarnera G, et al. Vitamin D serum levels in patients with statin-induced musculoskeletal pain. Dis Markers. 2019;2019:3549402.
   PubMed Web of Science ®Google Scholar
• Kang JH, Nguyen QN, Mutka J, et al. Rechallenging statin therapy in veterans with statin-induced myopathy post Vitamin D replenishment. J Pharm Pract. 2017 Oct;30(5):521–527.
   PubMedGoogle Scholar
• Serban MC, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017 Mar 21;69(11):1386–1395.
   PubMed Web of Science ®Google Scholar
• Awad K, Mikhailidis DP, Toth PP, et al. Efficacy and safety of alternate-day versus daily dosing of statins: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2017 Aug;31(4):419–431.
   PubMed Web of Science ®Google Scholar
• Taha DA, Zgair A, Lee JB, et al. Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity. Eur J Pharm Sci. 2017 Mar;30(100):163–175.
   Web of Science ®Google Scholar
• Lacaze P, Woods R, Zoungas S, et al. The genomic potential of the aspirin in reducing events in the elderly and statins in reducing events in the elderly studies. Intern Med J. 2017 Apr;47(4):461–463.
   PubMed Web of Science ®Google Scholar
• Shakir MKM, Shin T, Hoang TD, et al. Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab (Praluent). J Clin Lipidol. 2017 Nov - Dec;11(6):1485–1487.
   PubMed Web of Science ®Google Scholar
• Balestrino M, Adriano E. Statin-induced myopathy prevented by creatine administration. BMJ Case Rep. 2018 Aug 27;2018. pii: bcr-2018-225395. doi: 10.1136/bcr-2018-225395.
   PubMedGoogle Scholar
• Chan SL, Tham MY, Tan SH, et al. Development and validation of algorithms for the detection of statin myopathy signals from electronic medical records. Clin Pharmacol Ther. 2017 May;101(5):667–674.
   PubMed Web of Science ®Google Scholar
• Sai K, Hanatani T, Azuma Y, et al. Development of a detection algorithm for statin-induced myopathy using electronic medical records. J Clin Pharm Ther. 2013 Jun;38(3):230–235.
   PubMed Web of Science ®Google Scholar
• Vrablik M, Zlatohlavek L, Stulc T, et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res. 2014;63(Suppl 3):S327–34.
   PubMed Web of Science ®Google Scholar
• Hubacek JA, Adamkova V, Zlatohlavek L, et al. COQ2 polymorphisms are not associated with increased risk of statin-induced myalgia/myopathy in the Czech population. Drug Metab Pers Ther. 2017 Dec 20;32(4):177–182.
   PubMedGoogle Scholar
• Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019 Apr 2;8(7):e011662.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018 Oct;277:195–203.
   PubMed Web of Science ®Google Scholar
• Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011 May;10(3):373–387.
   PubMed Web of Science ®Google Scholar
• Settergren J, Eiermann B, Mannheimer B. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy–a nationwide register study. PLoS One. 2013;8(8):e69545.
   PubMed Web of Science ®Google Scholar
• Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010 Mar 1;33(3):171–187.
   PubMed Web of Science ®Google Scholar
• Mitchell D, Guertin JR, Dubois A, et al. A discrete event simulation model to assess the economic value of a hypothetical pharmacogenomics test for statin-induced myopathy in patients initiating a statin in secondary cardiovascular prevention. Mol Diagn Ther. 2018 Apr;22(2):241–254.
   PubMed Web of Science ®Google Scholar
• Mitchell D, Guertin JR, LeLorier J. Value of a hypothetical pharmacogenomic test for the diagnosis of statin-induced myopathy in patients at high cardiovascular risk. Mol Diagn Ther. 2018 Dec;22(6):641–652.
   PubMed Web of Science ®Google Scholar
• Loganathan P, Oddis CV, Aggarwal R. Immune-mediated statin myopathy. Expert Rev Clin Immunol. 2016;12(1):33–38.
   PubMed Web of Science ®Google Scholar
• Sharma P, Timilsina B, Adhikari J, et al. Statin-induced necrotizing autoimmune myopathy: an extremely rare adverse effect from statin use. J Community Hosp Intern Med Perspect. 2019;9(6):503–506.
   PubMed Web of Science ®Google Scholar
• Saleh Y, Herzallah K, Hassanein M, et al. Statin-induced necrotizing autoimmune myopathy: an uncommon complication of a commonly used medication. J Saudi Heart Assoc. 2019 Oct;31(4):269–272.
   PubMed Web of Science ®Google Scholar
• Penson PE, Mancini GBJ, Toth PP, et al. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1023–1033.
   PubMed Web of Science ®Google Scholar
• Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother. 2013 Mar;47(3):398–404.
   PubMed Web of Science ®Google Scholar